Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

  • days left to enroll
  • participants needed
  • sponsor
    Ottawa Hospital Research Institute
Updated on 23 September 2021
antiviral therapy
liver failure
nucleoside analog
hepatitis b antigen
antiviral drugs
hepatitis b e antigen
hepatitis b surface
hepatitis d


Hepatitis B virus (HBV) leads to life-threatening disease like liver failure and liver cancer. For most, a cure is unattainable as current HBV antiviral therapy (using nucleoside analogues) are not able to clear the virus from their liver. While HBV treatments are typically administered alone (monotherapy), this study will explore the use of Ribavirin in combination with standard therapy to enhance current treatment regimens. Ribavirin is commonly used to treat Hepatitis C Virus (HCV) but there is evidence that Ribavirin also induces immune effects that are beneficial in HBV treatment. The aim of this study is to determine whether combination of Ribavirin and a nucleoside analog is more effective compared to nucleoside analog treatment alone. Enrolled patients will be followed for treatment response according to standard clinical and virological tests, as well as immune response to HBV. Our ultimate goal is to find a more effective treatment and improve health outcomes for persons living with HBV.

Condition chronic hepatitis b
Treatment Ribavirin, tenofovir
Clinical Study IdentifierNCT03759782
SponsorOttawa Hospital Research Institute
Last Modified on23 September 2021


Yes No Not Sure

Inclusion Criteria

HBV Hepatitis B surface antigen (HBsAg) positive for a minimum of 24 weeks
HBV DNA level >20,000 IU/mL
18 years of age

Exclusion Criteria

Willingness and ability to sign an informed consent
HBV nucleos(t)ides and/or interferon exposure within 24 weeks of study medication dosing
HIV and other immune compromising condition (e.g. cancer with the exception of non-invasive cutaneous malignancy, autoimmune condition) or therapy (i.e. systemic steroids, chemotherapy)
HCV co-infected
Cirrhosis (defined by biopsy criteria or as >18.4 kilopascal (kPa) by transient elastography)
Creatinine Clearance <60 ml/min
Baseline hemoglobin <130 g/L in males and <120 g/L in females
Unwilling or unable to use contraception (unless confirmed surgical sterilization)
Pregnancy confirmed by blood test
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note